Inmazeb use while Breastfeeding

Summary of Use during Lactation

Inmazeb is a mixture of monoclonal antibodies, atoltivimab, maftivimab, and odesivimab that are directed against Zaire ebolavirus glycoprotein. No information is available on the use of Inmazeb during breastfeeding. Because Inmazeb is a mixture of large protein molecules with molecular weights of 144,000 to 146,000 Da, the amount in milk is likely to be very low and absorption is unlikely because the antibodies are probably destroyed in the infant's gastrointestinal tract. Until more data become available, Inmazeb should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. The US Centers for Disease Control and Prevention recommend that patients with confirmed Zaire ebolavirus not breastfeed their infants to reduce the risk of postnatal transmission of Zaire ebolavirus infection.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Name

Inmazeb

CAS Registry Number

2135632-29-8; 2135632-36-7; 2135632-30-1

Drug Class

Breast Feeding

Lactation

Milk, Human

Antibodies, Monoclonal

Antibodies, Viral

Antiviral Agents